How patients with multiple sclerosis weigh treatment risks and benefits

Area of Science:

• Neuroscience
• Health Psychology
• Clinical Pharmacy

Background:

• Established efficacy and risks of multiple sclerosis (MS) therapies are known.
• Limited understanding exists regarding patient perception and risk-benefit analysis of MS treatments.
• Understanding patient risk-benefit trade-offs is crucial for therapy development, approval, and recommendation.

Purpose of the Study:

• To describe individual differences in how patients with MS weigh risks and benefits when making treatment decisions.
• To explore factors influencing patient willingness to initiate disease-modifying therapies (DMTs).

Main Methods:

• 290 patients with MS completed tasks assessing willingness to take hypothetical DMTs.
• Assessments included varying efficacy, side effect probability, and severity.
• Questionnaires covered MS knowledge, medication beliefs, healthcare climate, and disease severity.

Main Results:

• Patients with primary progressive MS showed higher DMT willingness than those with relapsing-remitting or secondary progressive MS.
• Lower willingness to initiate DMTs was observed in patients who had never used DMTs, held more alternative health beliefs, or had discontinued DMTs due to side effects.
• Increased MS knowledge correlated with greater willingness to initiate DMTs.

Conclusions:

• This study provides initial insights into how chronic disease patients balance medication risks and benefits.
• Findings have implications for pharmaceutical development, physician-patient communication, adherence strategies, and patient education.
• Further research can enhance understanding of patient decision-making in chronic disease management.